Related Experiment Video
Updated: Apr 11, 2026
09:52
Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
11.2K
An update on pediatric invasive aspergillosis
P Frange1, M-E Bougnoux2, F Lanternier3
1Laboratoire de microbiologie clinique, hôpital Necker-Enfants-Malades, Assistance publique-Hôpitaux de Paris (AP-HP), 149, rue de Sèvres, 75015 Paris, France; Unité d'immunologie, hématologie et rhumatologie pédiatriques, hôpital Necker-Enfants-Malades, AP-HP, 75015 Paris, France; EA 7327, université Paris Descartes, Sorbonne-Paris-Cité, 75015 Paris, France.
Medecine Et Maladies Infectieuses
|June 1, 2015
Summary
Invasive aspergillosis (IA) in children is rising, with limited diagnostic data and treatment guidelines. New pediatric-specific antifungal strategies are crucial for better outcomes.
Area of Science:
- Medical Mycology
- Pediatric Infectious Diseases
- Clinical Pharmacology
Background:
- Invasive aspergillosis (IA) presents a significant challenge in immunocompromised pediatric populations, with increasing incidence.
- Current diagnostic tools and treatment protocols for IA in children are often extrapolated from adult data, highlighting a critical knowledge gap.
Purpose of the Study:
- To consolidate epidemiological, clinical, and biological data on IA in pediatric patients.
- To review current and potential antifungal treatment strategies specifically for children.
- To identify the need for pediatric-adapted antifungal formulations and evaluations.
Main Methods:
- Systematic review of existing literature on invasive aspergillosis in children.
- Analysis of diagnostic utility of biological assays (galactomannan, β-D-glucan, Aspergillus DNA) in pediatric populations.
- Evaluation of current treatment recommendations and pharmacokinetic/pharmacodynamic data for antifungals in pediatric IA.
Main Results:
- Limited pediatric-specific data exists for diagnostic assays, showing variable sensitivity and specificity.
- Pediatric treatment guidelines are largely derived from adult studies, necessitating cautious application.
- There is a clear need for research into novel antifungal formulations tailored for pediatric use.
Conclusions:
- Invasive aspergillosis management in children requires specialized approaches due to unique physiological and immunological factors.
- Development and evaluation of pediatric-specific antifungal agents and diagnostic markers are essential.
- Further research is imperative to improve the diagnosis and treatment of IA in infants and children.
Keywords:
Antifungal therapyAspergilloses invasivesInvasive aspergillosisPediatricsPédiatrieTraitement antifongiqueMore Related Videos
Related Concept Videos
01:28Pneumonia IV: Management
1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
01:26Pulmonary Tuberculosis IV
743
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
743
01:15Antifungal Agents
81
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
81
01:30Pneumonia III: Complications and Assessment
1.3K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.3K
01:14Atypical Pneumonia
57
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
57
01:30Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K